The Echinocandins

@article{Cappelletty2007TheE,
  title={The Echinocandins},
  author={D. Cappelletty and Kasi Eiselstein-McKitrick},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2007},
  volume={27}
}
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin. These agents have a broad spectrum of activity and are similar to each other with respect to in vitro activity against Candida sp, with micafungin and anidulafungin having… Expand
108 Citations
Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on Candida parapsilosis
  • 2
Echinocandin pharmacodynamics: review and clinical implications.
  • 52
  • PDF
FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance
  • 110
  • PDF
Echinocandins: The Newest Class of Antifungals
  • 153
Differential Aspergillus lentulus Echinocandin Susceptibilities Are Fksp Independent
  • 27
  • PDF
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
  • 237
  • Highly Influenced
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 118 REFERENCES
Comparison of caspofungin and amphotericin B for invasive candidiasis.
  • 938
Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents.
  • 34
  • PDF
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
  • 519
  • PDF
...
1
2
3
4
5
...